According to the completion response letter, the FDA requested additional information about Insulin Icodec’s manufacturing process and its indication for type 1 diabetes before completing its review.
FDA issues complete response letter to Novo Nordisk regarding Icodec, a once-weekly basal insulin for the treatment of diabetes
Leave a comment
